Reassessing Diabetes and APOE Genotype as Potential Interacting Risk Factors for Alzheimer’s Disease

American Journal of Alzheimer's Disease &Other Dementias®, Volume 37, Issue , January-December 2022. Objective: To assess whether diabetes alone or in association with Apolipoprotein E (APOE) ε4 genotype increases the risk of Alzheimer’s Disease (AD) diagnosis. Methods: A retrospective cohort study of 33,456 participants from the National Alzheimer’s Coordinating Center database. Results: Participants with one or two APOE ε4 alleles had 2.71 (CI:2.55–2.88) and 9.37 (CI:8.14–10.78) times hig...
More

The Auditory P50 Gating in Mild Cognitive Impairment: A Case-Control Study

American Journal of Alzheimer's Disease &Other Dementias®, Volume 37, Issue , January-December 2022. Objective: Auditory P50 gating changed might be a neurophysiological biomarker of the diagnosis of Mild Cognitive Impairment (MCI). We aimed to determine the impact of MCI in auditory P50 gating. Methods: All recruited participants completed structured questionnaires and finished auditory P50 gating measure. Results: A total of 20 MCI patients and 17 controls had been recruited. MCI patients...
More

Perceived Stress in Older Dementia Caregivers: Mediation by Loneliness and Depression

American Journal of Alzheimer's Disease &Other Dementias®, Volume 37, Issue , January-December 2022. Coupled with aging, chronic stress experienced by dementia caregivers often leads to deteriorating health. Comparing caregivers and non-caregivers, we tested whether depression and loneliness mediate the relationship between caregiver status and a measure of chronic stress, the Perceived Stress Scale. Seventy-six cognitively normal older adults (mean age 72.7) were identified as caregivers o...
More

Proton Pump Inhibitors and Risk of Dementia: A Hypothesis Generated but Not Adequately Tested

American Journal of Alzheimer's Disease &Other Dementias®, Volume 36, Issue , January-December 2021. We reviewed the evidence on proton pump inhibitors (PPIs) and dementia. PPIs are among the most widely utilized drugs in the world. Dementia affects roughly 5% of the population of the United States (US) and world aged 60 years and older. With respect to PPIs and dementia, basic research has suggested plausible mechanisms but descriptive and analytic epidemiological studies are not inconsist...
More

Effect of Multiple Medicines on Dementia Initial Treatment: Experience and Thinking

American Journal of Alzheimer's Disease &Other Dementias®, Volume 36, Issue , January-December 2021. Little is known about multiple medicines and initial therapy among people with dementia. To examine the effect of multiple medicines on the initiation of anti-dementia therapy in patients diagnosed with cognitive impairment (CI), a retrospective study with 2742 CI patients was conducted based on the outpatients’ medical records. The dementias receiving 1–2 drugs were more likely to be prescr...
More